Please assess the completion status of the following clinical trial:

Trial Title: Long-term Cardiac Monitoring in Epilepsy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18-50 years with ability to consent.~2. No primary cardiac abnormality.~3. Ability to receive an implantable loop recorder and tolerate the procedure.~4. Patients with epilepsy as described by the three groups (intractable focal epilepsy, controlled focal epilepsy and symptomatic generalized epilepsy)~Exclusion Criteria:~1. Cardiac disease of any type~2. Known epilepsy genetic disorder with potential cardiac compromise~3. Major co-morbidities such as cancer, diabetes, stroke, bleeding disorder~4. Chronic psychosis~5. Severe MR without reliable caregiver monitoring (what is MR?)~6. Already included in another clinical trial that will affect the objectives of this study.~7. Life expectancy is less than 1 year

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- LINQ ICM (Type: EXPERIMENTAL): The LINQ ICM (Medtronic, Inc.) is a small FDA approved cardiac monitor implanted in the subcutaneous tissue of the chest wall that is designed to continuously record a single-lead ECG, monitoring the cardiac rhythm for up to three years. The device records and stores patient's rhythm on two occasions: first when programmed criteria are met and second upon patient activation. These programmable arrhythmia criteria are based on heart rate (bradycardia, tachycardia), irregularity of heart rate and duration of rate disturbance. The LINQ ICM (or future iterations) will be utilized in this study to detect arrhythmias in our study population. The LINQ ICM is approved by the FDA for use in patients where there is a suspicion of occult cardiac arrhythmias and is therefore being utilized in this study in accordance with the FDA labeling.

Based on this trial design, predict the completion outcome and termination type (if applicable).